Envisagenics Announces Research Program with the Lung Cancer Initiative at Johnson & Johnson

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

Red Dot Best of the Best Award for Voice-controlled Surgical Loupes Goes to Sagentia Innovation

A voice-controlled surgical loupe headset, sPEEK, designed by Sagentia Innovation’s multidisciplinary team has been awarded a coveted Red Dot: Best of the Best award...

Envisagenics is a company developing therapeutics for RNA splicing errors that often lead to genetic disorders including cancer, announced today that it has entered into a research program agreement with the Lung Cancer Initiative (LCI) at Johnson & Johnson. Through this initiative, Envisagenics will build predictive models for lung cancer progression and risk. The Envisagenics team will leverage its expertise in splicing and RNA-sequencing to analyze LCI’s data using Envisagenics’ SpliceCore® software platform.

“Lung cancer is the leading cause of cancer-related deaths globally, and it is difficult to treat in later stages,” said Maria Luisa Pineda, Ph.D., co-founder and Chief Executive Officer of Envisagenics. “That is why it is so important for Envisagenics to identify early determinants of lung cancer risk. Envisagenics hopes to identify RNA splicing events that can predict lung cancer, and in the future, develop new therapies for patients.”

Martin Akerman, Ph.D., co-founder and Chief Technology Officer of Envisagenics, commented, “Tumor cells can literally cut-and-paste RNAs to produce unique cancerous proteins. Detecting these RNA splicing events early could mean better prognoses for lung cancer patients. SpliceCore can extract these biological insights because it can scan through millions of potential RNA splicing events from 1,000 patient samples in two hours.”

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.